DV

Dr. Tanja Vukicevic

Vice President Of Business Development at Proteros

Dr. Tanja Vukicevic has diverse work experience in various roles and industries. Dr. Tanja is currently the Vice President of Business Development at PROTEROS biostructures GmbH since August 2023. Prior to this, they worked at Leukocare AG from May 2019 to April 2023, starting as a Business Development Manager and progressing to become the Director/Head of Business Development. Dr. Tanja also worked as a Sales Manager at ITG Isotope Technologies Garching GmbH from September 2017 to April 2019. Dr. Vukicevic has a background in research, having served as a Researcher PhD Student at the Max Delbrück Center for Molecular Medicine from August 2014 to July 2017. Additionally, they have experience as a Managing Director and Founder of Pharmacy "Maslačak" from April 2010 to December 2015. Dr. Vukicevic has also taken on teaching roles as a Teaching Assistant at the Faculty of Pharmacy in Niš, Serbia from 2005 to 2012. Dr. Tanja started their career as a Pharmacist intern at a community pharmacy from February 2009 to January 2010.

Dr. Tanja Vukicevic earned a Master's Degree in Pharmacy from the University of Niš from 2003 to 2009. Dr. Tanja then pursued their academic career and obtained a degree of Dr. rer. nat. in Molecular Medicine from the Freie Universität Berlin between 2014 and 2017. Additionally, they obtained a certification in The Pharma Licensing Negotiation Course with Dr. Roger Cox from CELforPharma in 2022.

Location

Munich, Germany

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Proteros

Proteros is a biotech company focused on enabling lead discovery for challenging targets. Proteros has established a profitable discovery service business with a best-in-class enabling technology platform for structure accelerated lead discovery. Their track record is proven by an outstanding project success rate. Proteros’ proprietary pipelineincludes highly disease relevant target classes such as kinases, epigenetic targets and GPCRs. Their success is built on unique know how and expertise in understanding the role of protein structures involved in protein and small molecule interactions that are responsible for the pathogenesis of many diseases.


Industries

Links